SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is facing extreme volatility as investors weigh a strongly critical FDA briefing document against potential support from patient advocacy groups and physicians ahead of the upcoming advisory committee meeting. Market sentiment remains fractured, with the community intensely debating whether the company can overcome persistent regulatory hurdles regarding trial design and data integrity or if a third Complete Response Letter is inevitable.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is generating significant community interest as investors actively debate the project's long-term utility versus its recent price volatility. While some participants are aggressively accumulating during market dips, others remain focused on upcoming regulatory milestones like the Clarity Act and the potential impact of ecosystem growth and staking participation on future token value.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA approval of Auvelity for the treatment of agitation in Alzheimer's disease, a massive new market segment that significantly expands the company's growth potential beyond its existing depression indication. Investors and community members are actively discussing the company's aggressive peak sales projections and the upcoming quarterly earnings report, with many looking for signs of how quickly this new commercial launch will drive revenue.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors weigh the potential for a strategic turnaround under new CEO Michael Severino against ongoing concerns regarding valuation, short interest, and competitive pressures in the DMD space. The community remains deeply divided, with many debating whether the stock's current price represents a distressed buying opportunity or an ongoing decline.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors weigh the potential impact of an ongoing Supreme Court case against the company's recent report of positive cash flow and reduced operating expenses. The community remains deeply divided, with some highlighting the stock's low valuation relative to its cash position while others express frustration over management's lack of transparent strategic direction and the lack of a clear timeline for a buyout.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is currently trading in a sensitive consolidation phase as investors weigh significant geopolitical risks and potential market volatility against expectations for the upcoming earnings report. The community remains actively divided, with many debating the technical probability of a gap-fill to lower support levels versus a robust post-earnings rally fueled by continued enterprise demand for AI data engineering.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is trending as community optimism surges behind a governance proposal to activate a fee switch and initiate a large-scale token burn, aimed at enhancing deflationary pressure. Traders are actively debating whether these fundamental updates will act as a sufficient catalyst to drive a sustained price breakout despite broader market volatility.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is currently trending as community members debate the long-term potential of the Goliath mainnet launch and its utility for institutional finance. While some investors are actively accumulating and staking in anticipation of future adoption and regulatory clarity, others are vocal about their frustration regarding extended periods of stagnant price action and past marketing hype.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is attracting renewed investor attention as analysts highlight potential upside from the company's streaming profitability and park performance, despite ongoing community debate regarding the stock's long-term price stagnation. The discourse is currently split between bulls betting on a rebound driven by recent box office success and streaming shifts, and vocal bears skeptical of the company's creative direction and management.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is drawing intense attention due to its unique model where the majority of platform fees are automatically funneled into token buybacks, creating a direct feedback loop between trading volume and price. Community sentiment is deeply divided, with many traders viewing recent volatility as a prime accumulation opportunity for long-term growth while others caution that the current price action reflects speculative hype rather than fundamental value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alkermes plc Reports Second Quarter 2026 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the companys investor relations website at https://investor.alkermes.com. Alkermes will host a conference...

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance

AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the companys second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes...

Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study

Alkermes reports positive long-term data for alixorexton, showing sustained wakefulness and symptom improvements in NT1 and NT2 narcolepsy.read more...

Alkermes Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton...

$ALKS Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.00
• Reported revenue of $496.01M up 26.97% YoY
• Alkermes plc updated its 2026 expectations, now projecting a GAAP net loss of $95 million to $115 million and EBITDA of $75 million to $95 million, while maintaining other financial guidance.

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.04	--	--	N/A
Q2 '26	-$0.02	$0.00	100.00%	BEAT
Q1 '26	-$0.54	-$0.40	26.01%	BEAT
Q4 '25	$0.41	$0.29	-29.77%	MISSED
Q3 '25	$0.37	$0.68	84.71%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings